Home/AAVogen/Alexandra McPherron, PhD

AM

Alexandra McPherron, PhD

Chief Scientific Officer (CSO)

Therapeutic Areas

Muscle Wasting Diseases Neuromuscular Diseases Cardiovascular Disease

AAVogen Pipeline

Drug	Indication	Phase
AVGN7	Inclusion Body Myositis (IBM)	Pre-clinical
AVGN7 + AVGND	Duchenne Muscular Dystrophy (DMD)	Pre-clinical

Leadership Team at AAVogen

Buel "Dan" Rodgers, PhD

Jade Brown, MBA

Business Development Director

Chris Novashinski

Regulatory Affairs Director, Co-Founder & COO (RareMoon)

Joseph Rininger, PhD

Gary Carswell, CPA

CFO (contracted)

View full AAVogen profile